June 3, 2013
Nuvilex Could Help Shape the Future of Medical Marijuana
Spurred on by public outcries for broader medical marijuana availability in order to treat cancer patients, Nuvilex Inc. (OTCQB – NVLX- $0.1385 – Spec Buy - $0.75 Target) stands ready to engage in comprehensive research and development that could eventually result in landmark therapeutic success. The Company is poised to meld its highly regarded live cell-encapsulation technology to treat certain cancers in clinical trials and other tests, with the use of cannabinoids which have demonstrated an ability to act anticancer agents in various studies. Clearly, this live-cell encapsulation technology and cannabinoid combination is both proprietary and unique relative to anything the market has seen to date.
Although nearly two dozen states have passed some sort of medical marijuana legislation, gaining access to the product is not always an easy task. The roadblocks and hurdles have been especially hard on patients stricken with various forms of cancer. However, public outcries and mainstream media interviews with these patients who are now obtaining the product illegally have gone viral, as have the many stories regarding the purported benefits that the medical marijuana active agents have had a major effect on their disease progression and management.
Unlike most firms engaged in research and development in the medical marijuana space, Nuvilex is not focused on pain management or nausea, etc. Since the basis of its platform live-cell encapsulation technology is to target the tumor, potentially inhibit progression, and treat it at its core, many cancer patients may monitor the Company’s progress with earnest, especially those who claim a halting in tumor progression due to use of medical marijuana.
In addition, since there are likely few safety and toxicity issues with medical marijuana, the development time may be shortened. Once sufficient volumes of cells and product are procured the Company can engage in a series of proper lab tests which could theoretically lead directly to Phase II human trials. Given the success of its pancreatic cancer trials and the clamor for true comprehensive medical marijuana research and development in oncology, Nuvilex is likely to garner quite a following as a leader in the space which is fast gaining allies and proponents, as evidenced by the recent Barron’s cover story (http://online.barrons.com/article/SB50001424052748704509304578511261557343002.html?mod=BOL_hpp_highlight_top#articleTabs_article%3D1).
Senior Analyst: Robert Goldman
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.